Attacker Criticizes Kunka’s State in Patch 7.36
Attacker, known as one of Dota 2‘s popular pubstars, has expressed his dissatisfaction with the current state of the hero Kunkka following Patch 7.36. He has vowed not to play the hero until it receives a big buff or rework in a future release.
While Attacker did not delve into specific details during his recent stream on May 27, the Dota 2 subreddit has seen a wave of players sharing their frustrations regarding Kunkka’s changes post-Patch 7.36. The change to the X Mark duration has notably irritated many gamers, altering their gameplay strategy.
Dissecting Kunkka’s nerfs in Patch 7.36
Dota 2‘s Patch 7.36 introduced a series of nerfs to Kunkka, with the most notable being the adjustment to X Marks the Spot’s duration. This shift upset established player combos and muscle memory, forcing players to reconsider hero-based gameplay methods.
Furthermore, Kunkka’s intrinsic abilities and features were not spared in the most recent patch, resulting in a notable divergence between the hero’s kit and Valve’s planned approach.
Kunkka’s playstyle has evolved significantly over time, with modifications such as the revamp of Cleave Damage in Patch 7.20 changing the hero’s emphasis on Physical Damage. The addition of a new Aghanim Scepter upgrade moved Kunkka farther toward a mage caster role, deviating from prior glass cannon builds.
These modifications have altered Kunkka’s metagame position, resulting in an increase in popularity as a core hero from the Mid and Offlane positions. However, some gamers are disappointed with the deviation from the hero’s usual high-risk, high-reward gameplay.
As Kunkka’s pub win rate declines with Patch 7.36, Valve’s plans for the hero’s kit in future patches are called into doubt. The community remains confident that prospective buffs would address the difficulties mentioned by players such as Attacker and restore Kunkka to his former glory.
With letter patches on the horizon, only time will tell whether Kunkka will regain popularity and competitive viability.